Vanda Pharmaceuticals | VNDA - Operating Expenses


Vanda Pharmaceuticals reported $-1.14B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 526.79M 20.55M Jun/2026
J&J USD 18.93B 1.09B Sep/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Ligand Pharmaceuticals USD 55.1M 20.75M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 960M 817M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.92B 607M Jun/2026
Takeda JPY 1.02T 89.68B Jun/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Veracyte USD 126.36M 6.37M Jun/2026